May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?

Use este identificador para citar ou linkar para este item: http://repositorio.ufla.br/jspui/handle/1/41262

Registro completo de metadados

Campo DC	Valor	Idioma
dc.creator	Adamowicz, Jan	-
dc.creator	Juszczak, Kajetan	-
dc.creator	Drewa, Tomasz	-
dc.date.accessioned	2020-05-28T11:59:29Z	-
dc.date.available	2020-05-28T11:59:29Z	-
dc.date.issued	2020-07	-
dc.identifier.citation	ADAMOWICZ, J.; JUSZCZAK, K.; DREWA, T. May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications? Medical Hypotheses, [S.l.], v. 140, July 2020.	pt_BR
dc.identifier.uri	https://www.sciencedirect.com/science/article/abs/pii/S0306987720305909	pt_BR
dc.identifier.uri	http://repositorio.ufla.br/jspui/handle/1/41262	-
dc.description.abstract	COVID-19 pandemic is a major challenge for global and national healthcare providers. Number of new cases is continuously increasing with an emerging trend showing worse prognosis in males in comparison to females. Based on this observation, our proposed hypothesis is that 5-alpha-reductase inhibitors, that are commonly used for BPH treatment, may be one of the factors contributing to poorer prognosis in males.	pt_BR
dc.language	en_US	pt_BR
dc.publisher	Elsevier	pt_BR
dc.rights	restrictAccess	pt_BR
dc.source	Medical Hypotheses	pt_BR
dc.subject	COVID-19	pt_BR
dc.subject	5-alpha-reductase inhibitors	pt_BR
dc.title	May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?	pt_BR
dc.type	Artigo	pt_BR
Aparece nas coleções:	FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)

Arquivos associados a este item:

Não existem arquivos associados a este item.